Treatment of recurrent and uncontrolled malignant ovarian germ cell tumors.

doi:10.7504/fk2015020107

Abstract

Abstract:

Abstract:To study the clinical characteristic, the optimal treatments and the prognosis for the recurrent and uncontrolled malignant ovarian germ cell tumors(MOGCT).the few case of recurrent MOGCT were underwent comprehensive surgical staging.And most of them received the non-standard chemotherapy.When the malignant ovarian germ cell tumors were found again, the secondary debulking surgery was done.The former standard chemotherapy for patients was used.The critical treatment is the most important thing for the MOGCT.Even for the recurrence and uncontrolled MOGCT, the satisfied cytoreductive surgery plus the standard chemotherapy also show the significant impact on the prognosis of the recurrence and uncontrolled MOGCT patients.

Key words: malignant ovarian germ cell tumors, chemotherapy；uncontrolled；recurrence cancer

摘要：

恶性生殖细胞肿瘤治疗关键是规范化，包括手术切除肿瘤、手术病理分期、术后规范化疗，强调及时、足量、正规，可争取90%以上甚至100%的持续缓解率。初次化疗不规范，病情可能持续不缓解或复发。对于复发性恶性生殖细胞肿瘤，再次肿瘤细胞减灭术有减轻瘤负荷的作用，为术后的化疗奠定基础。复发性卵巢恶性生殖细胞肿瘤术后的二线化疗也至关重要。化疗药物应个体化，化疗的疗程数也强调个体化，有阳性肿瘤标志物的患者治疗应持续至肿瘤标志物降至正常后2个疗程。无阳性的肿瘤标志物的患者治疗应持续4~6个疗程。无性生殖细胞瘤和未成熟畸胎瘤对再次化疗或手术仍有效，预后好。卵黄囊瘤则效果很差。卵巢胚胎癌及原发绒癌很少见，治疗经验少。

关键词: 卵巢恶性生殖细胞肿瘤, 化疗, 耐药, 复发肿瘤

CLC Number:

R737.3

YANG Jia-xin，XIANG Yang.. Treatment of recurrent and uncontrolled malignant ovarian germ cell tumors.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020107.

杨佳欣，向阳. 复发性耐药性卵巢恶性生殖细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020107.

References

［1］   Dimopoulos MA, Papadimitriou C, Hamilos G, et al.Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide,and cisplatin regimen: a prospective multicenter study［J］.Gynecol Oncol，2004，95(3):695-700

［2］   Murugaesu N, Schmid P, Dancey G, et al.Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment［J］.J Clin Oncol，2006，24(30):4862-4866.

［3］   Li J, Yang W, Wu X.Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients［J］.Gynecol Oncol，2007，105(3):769-775.

［4］   Munkarah A, Gershenson DM, Levenback C, et al.Salvage surgery for chemorefractory ovarian germ cell tumors［J］.Gynecol Oncol，1994，55(2):217-223.

［5］   Messing MJ, Gershenson DM, Morris M, et al.Primary treatment failure in patients with malignant ovarian germ cell neoplasms［J］.Int J Gynecol Cancer ,1992,2(6):295-300.

［6］    Murphy BR, Breeden ES, Donohue JP, et al.Surgical salvage of chemorefractory germ cell tumors［J］.J Clin Oncol,1993,11(2):324-329.

［7］   Miki T, Mizutani Y, Nonomura N, et al.Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors［J］.Cancer,2002,95:1879-1885

［8］   Kondagunta GV, Bacik J, Donadio A, et al.Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors［J］.J Clin Oncol,2005,23(27):6549-6555.

［9］   Broun ER, Nichols CR, Turns M, et al.Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support［J］.Cancer,1994,73(6):1716-1720.

［10］    Schmoll HJ, Jordan K, Huddart R, et al.Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up［J］.Ann Oncol,2010,21(Suppl 5):v140-146.

［11］    Einhorn LH, Williams SD, Chamness A, et al.High-dose chemotherapy and stemcell rescue for metastatic germcell tumors［J］.N Engl J Med ,2007,357(4):340-348.

［12］   De Giorgi U, Rosti G, Salvioni R, et al.Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features［J］.Urol Oncol, In Press, Corrected Proof, Available online 24 June 2009, ISSN 1078-1439.

［13］    Nicolai N, Necchi A, Gianni L, et al.Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours［J］.BJU Int,2009,104(3):340-346.

［14］    Shiraishi T, Nakamura T, Mikami K, et al.Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors［J］.Int J Clin Oncol，2009，14(5):436-441.

［15］    Manchana T, Ittiwut C, Mutirangura A, et al.Targeted therapies for rare gynaecological cancers［J］.Lancet Oncol，2010，11(7):685-693 .

［16］    Looijenga LH, de Leeuw H, van Oorschot M, et al.Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germcell tumors［J］.Cancer Res，2003，63(22):7674-7678.

［17］    Einhorn LH, Brames MJ, Heinrich MC, et al.Phase Ⅱstudy of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT［J］.Am J Clin Oncol,2006,29(1):12-13.

［18］    Voigt W, Kegel T, Maher G, et al.Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer［J］.Ann Oncol,2006,17(3):531-533.

［19］    Mego M, Reckova M, Sycova-Mila Z, et al.Bevacizumab in a growing teratoma syndrome-case report［J］.Ann Oncol,2007,18(5):962-963.

（2014-11-20收稿）

[1]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(8): 769-772.
[2]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 673-675.
[3]	TAO Xiang, CHEN Ting-ting, ZHOU Xian-rong. Research status of histopathology and molecular pathology of gestational trophoblastic disease. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 676-680.
[4]	PENG Mei-lian, LIN Kai-wu, WENG Zong-jie, WU Qi-bin, SUN Peng-ming. . Imaging features and significance of gestational trophoblastic disease. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 680-684.
[5]	CHENG Guang-yan, QU Peng-peng.. Standardized management of hydatidiform mole. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 684-687.
[6]	LIU Xiao-mei, LI Xiu-qin.. Treatment for low-risk gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 687-691.
[7]	LI Ke-min, YIN Ru-tie. Treatment for high-risk gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 691-693.
[8]	CHENG Hong-yan, XIANG Yang. . Immunotherapy for gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 693-696.
[9]	WANG Fen-fen, BAO Ke-chun, CHENG Xiao-dong. Treatment for special pathological types of gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 696-701.
[10]	XI Ling, SUN Yue.. Fertility preservation in gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 701-704.
[11]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 705-713.
[12]	CHENG Ao-shuang, LIN Zhong-qiu. Protection and preservation of the fertility of female malignant tumor patients. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 604-609.
[13]	HUANG Chen-yang, SUN Hai-xiang. Selection of protocols about ovulation induction and embryo transfer for patients with gynecological malignant tumors. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 614-618.
[14]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 628-633.
[15]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 634-641.